Selank / Semax
A research-use-only two-component blend of two synthetic heptapeptides, each a short N-terminal sequence extended with a C-terminal Pro-Gly-Pro (glyproline) tripeptide that confers protease resistance.
Quick answers
What is Selank / Semax?
Selank / Semax is a blend of Selank and Semax.
How much published research cites Selank / Semax?
The Luvaminos Selank / Semax record cites 19 published references, dated 1997 to 2024. Each is listed on this page with a link to its source.
Does Luvaminos test Selank / Semax, and where is the certificate?
Luvaminos does not currently stock Selank / Semax. Every peptide lot Luvaminos sells is tested by Freedom Diagnostics Testing, PLLC, an independent laboratory, and its certificate is published at luvaminos.com/coa under the lot number printed on the vial.
How is Selank / Semax powder stored?
Sealed Selank / Semax powder: Store frozen and protected from light and moisture; commonly handled at -20°C for long-term storage as a sealed lyophilized powder. The C-terminal Pro-Gly-Pro motif confers resistance to enzymatic degradation; The methionine residue in Semax is susceptible to oxidation — protect from light and air. Avoid repeated freeze-thaw cycles.
How is Selank / Semax different from Selank?
Selank is a single compound; Selank / Semax is a blend of Selank and Semax, with Selank as one of its 2 components. Selank has 7 amino acids and a molecular weight of 751.88 g/mol.
How is Selank / Semax different from Semax?
Semax is a single compound; Selank / Semax is a blend of Selank and Semax, with Semax as one of its 2 components. Semax has 7 amino acids and a molecular weight of 813.93 g/mol.
Molecular Profile
- Type
- Peptide blend
Components
Selank
- Molecular formula
- C33H57N11O9
- Molecular weight
- ~751.9 g/mol
- CAS number
- 129954-34-3
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Semax
- Molecular formula
- C37H51N9O10S
- Molecular weight
- ~813.9 g/mol
- CAS number
- 80714-61-0
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Mechanism & Target Class
Both peptides belong to the 'glyproline-stabilized' class: a short N-terminal sequence is extended with a C-terminal Pro-Gly-Pro (PGP) tripeptide that slows proteolysis. Selank corresponds structurally to the tetrapeptide tuftsin sequence (Thr-Lys-Pro-Arg) carrying the C-terminal PGP extension, giving the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Semax is a synthetic peptide corresponding to the ACTH(4-7) sequence (Met-Glu-His-Phe) carrying the same C-terminal PGP extension, giving the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro; its N-terminal methionine residue is susceptible to oxidation. The shared PGP scaffold is the common structural feature characterized across both molecules, and the C-terminal glyproline motif is described in the chemistry literature as the modification that resists enzymatic degradation.
Storage & Handling
- Lyophilized
- Store frozen and protected from light and moisture; commonly handled at -20°C for long-term storage as a sealed lyophilized powder.
- Handling
- The C-terminal Pro-Gly-Pro motif confers resistance to enzymatic degradation; The methionine residue in Semax is susceptible to oxidation — protect from light and air. Avoid repeated freeze-thaw cycles. For research use only; not for human or veterinary use.
References (19)
Reviews
1Dergunova LV, Filippenkov IB, Limborska SA, et al. (2023). Genes (Basel)
- 2
Koroleva SV, Myasoedov NF. (2018). Biology Bulletin
- 3
Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. (2018). Protein and Peptide Letters
Clinical
4Gusev EI, Martynov MY, Kostenko EV, et al. (2018). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
- 5
Medvedev VE, Tereshchenko ON, Kost NV, et al. (2015). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
- 6
Zozulya AA, Neznamov GG, Syunyakov TS, et al. (2008). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
- 7
Uchakina ON, Uchakin PN, Miasoedov NF, et al. (2008). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
- 8
Gusev EI, Skvortsova VI, Miasoedov NF, et al. (1997). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Primary research
9Inozemtseva LS, Yatsenko KA, Glazova NYu, et al. (2024). European Journal of Pharmacology
- 10
Panikratova YaR, Lebedeva IS, Sokolov OYu, et al. (2020). Doklady Biological Sciences
- 11
Filatova E, Kasian A, Kolomin T, et al. (2017). Frontiers in Pharmacology
- 12
Kasian A, Kolomin T, Andreeva L, et al. (2017). Behavioural Neurology
- 13
Volkova A, Shadrina M, Kolomin T, et al. (2016). Frontiers in Pharmacology
- 14
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. (2014). BMC Genomics
- 15
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008). Doklady Biological Sciences
- 16
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Brain Research
- 17
Eremin KO, Kudrin VS, Saransaari P, et al. (2005). Neurochemical Research
- 18
Kost NV, Sokolov OYu, Gabaeva MV, et al. (2001). Russian Journal of Bioorganic Chemistry
- 19
Zozulya AA, Kost NV, Sokolov OYu, et al. (2001). Bulletin of Experimental Biology and Medicine
Related compounds